RenovoRx (RNXT) Competitors

$0.88 +0.07 (+8.83%)

Closing price 05/21/2026 04:00 PM Eastern

Extended Trading

$0.92 +0.04 (+4.81%)

As of 05/21/2026 07:44 PM Eastern

RNXT vs. VTVT, PYXS, GNLX, ACOG, and OKUR

Should you buy RenovoRx stock or one of its competitors? MarketBeat compares RenovoRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RenovoRx include vTv Therapeutics (VTVT), Pyxis Oncology (PYXS), Genelux (GNLX), Alpha Cognition (ACOG), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical products" industry.

How does RenovoRx compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 9.1% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

RenovoRx has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	137.13	-$26.97M	-$0.93	N/A
RenovoRx	$1.12M	35.50	-$11.17M	-$0.33	N/A

vTv Therapeutics presently has a consensus target price of $53.00, indicating a potential upside of 49.30%. RenovoRx has a consensus target price of $8.25, indicating a potential upside of 835.80%. Given RenovoRx's higher probable upside, analysts clearly believe RenovoRx is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

vTv Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, RenovoRx has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

In the previous week, RenovoRx had 4 more articles in the media than vTv Therapeutics. MarketBeat recorded 17 mentions for RenovoRx and 13 mentions for vTv Therapeutics. RenovoRx's average media sentiment score of 0.60 beat vTv Therapeutics' score of 0.33 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. vTv Therapeutics' return on equity of 3.96% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

RenovoRx beats vTv Therapeutics on 9 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Pyxis Oncology and Pyxis Oncology both had 17 articles in the media. RenovoRx's average media sentiment score of 0.60 beat Pyxis Oncology's score of 0.20 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
RenovoRx	-823.98%	-135.03%	-101.92%

Pyxis Oncology has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

Pyxis Oncology presently has a consensus price target of $6.83, indicating a potential upside of 252.23%. RenovoRx has a consensus price target of $8.25, indicating a potential upside of 835.80%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts plainly believe RenovoRx is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by insiders. Comparatively, 9.1% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

RenovoRx has lower revenue, but higher earnings than Pyxis Oncology. RenovoRx is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	8.87	-$79.62M	-$1.31	N/A
RenovoRx	$1.12M	35.50	-$11.17M	-$0.33	N/A

Summary

Pyxis Oncology and RenovoRx tied by winning 8 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Genelux?

Genelux (NASDAQ:GNLX) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

RenovoRx has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A
RenovoRx	$1.12M	35.50	-$11.17M	-$0.33	N/A

In the previous week, RenovoRx had 17 more articles in the media than Genelux. MarketBeat recorded 17 mentions for RenovoRx and 0 mentions for Genelux. RenovoRx's average media sentiment score of 0.60 beat Genelux's score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
RenovoRx	Positive

Genelux has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
RenovoRx	-823.98%	-135.03%	-101.92%

Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 516.44%. RenovoRx has a consensus price target of $8.25, suggesting a potential upside of 835.80%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts plainly believe RenovoRx is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

37.3% of Genelux shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 9.1% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genelux has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, RenovoRx has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

Summary

RenovoRx beats Genelux on 13 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

3.1% of RenovoRx shares are held by institutional investors. 14.0% of Alpha Cognition shares are held by company insiders. Comparatively, 9.1% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

RenovoRx has lower revenue, but higher earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.83M	11.71	-$20.67M	-$1.35	N/A
RenovoRx	$1.12M	35.50	-$11.17M	-$0.33	N/A

Alpha Cognition currently has a consensus target price of $16.00, suggesting a potential upside of 174.91%. RenovoRx has a consensus target price of $8.25, suggesting a potential upside of 835.80%. Given RenovoRx's higher possible upside, analysts plainly believe RenovoRx is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, RenovoRx had 12 more articles in the media than Alpha Cognition. MarketBeat recorded 17 mentions for RenovoRx and 5 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 0.70 beat RenovoRx's score of 0.60 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Alpha Cognition has a net margin of -232.23% compared to RenovoRx's net margin of -823.98%. Alpha Cognition's return on equity of -58.35% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

Alpha Cognition and RenovoRx tied by winning 8 of the 16 factors compared between the two stocks.

How does RenovoRx compare to OnKure Therapeutics?

RenovoRx (NASDAQ:RNXT) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, RenovoRx had 16 more articles in the media than OnKure Therapeutics. MarketBeat recorded 17 mentions for RenovoRx and 1 mentions for OnKure Therapeutics. RenovoRx's average media sentiment score of 0.60 beat OnKure Therapeutics' score of 0.00 indicating that RenovoRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OnKure Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. OnKure Therapeutics' return on equity of -61.02% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
OnKure Therapeutics	N/A	-61.02%	-55.99%

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 9.1% of RenovoRx shares are held by insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

RenovoRx has higher revenue and earnings than OnKure Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	35.50	-$11.17M	-$0.33	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

RenovoRx has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, OnKure Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

RenovoRx currently has a consensus price target of $8.25, suggesting a potential upside of 835.80%. OnKure Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 563.39%. Given RenovoRx's stronger consensus rating and higher possible upside, equities analysts clearly believe RenovoRx is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

RenovoRx beats OnKure Therapeutics on 11 of the 16 factors compared between the two stocks.

Get RenovoRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNXT vs. The Competition

Export

Metric	RenovoRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$36.53M	$3.34B	$6.35B	$12.29B
Dividend Yield	N/A	2.29%	2.79%	5.33%
P/E Ratio	-2.67	18.53	21.08	25.34
Price / Sales	35.50	286.26	528.17	80.04
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	3.53	6.92	10.00	7.01
Net Income	-$11.17M	$24.39M	$3.55B	$335.27M
7 Day Performance	7.51%	2.68%	1.99%	1.28%
1 Month Performance	-7.03%	-1.45%	-0.87%	0.16%
1 Year Performance	-28.33%	62.18%	36.38%	34.54%

RenovoRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNXT RenovoRx	3.8326 of 5 stars	$0.88 +8.8%	$8.25 +835.8%	-27.7%	$36.53M	$1.12M	N/A	6	Analyst Revision Gap Up
VTVT vTv Therapeutics	2.8513 of 5 stars	$36.49 +2.8%	$53.00 +45.2%	+83.5%	$139.79M	$1.02M	N/A	9	Analyst Revision
PYXS Pyxis Oncology	3.3356 of 5 stars	$1.91 -5.4%	$6.83 +257.8%	+68.7%	$127.98M	$13.86M	N/A	60	Analyst Revision
GNLX Genelux	1.6467 of 5 stars	$2.80 -1.8%	$18.00 +542.9%	+17.3%	$127.79M	$10K	N/A	10
ACOG Alpha Cognition	4.3828 of 5 stars	$5.80 +0.9%	$16.00 +175.9%	-40.9%	$125.20M	$10.22M	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNXT) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RenovoRx (RNXT) Competitors

RNXT vs. VTVT, PYXS, GNLX, ACOG, and OKUR

How does RenovoRx compare to vTv Therapeutics?

Summary

How does RenovoRx compare to Pyxis Oncology?

Summary

How does RenovoRx compare to Genelux?

Summary

How does RenovoRx compare to Alpha Cognition?

Summary

How does RenovoRx compare to OnKure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RenovoRx (RNXT) Competitors

RNXT vs. VTVT, PYXS, GNLX, ACOG, and OKUR

How does RenovoRx compare to vTv Therapeutics?

Do insiders & institutionals have more ownership in VTVT or RNXT?

Which has higher valuation and earnings, VTVT or RNXT?

Do analysts rate VTVT or RNXT?

Which has more risk & volatility, VTVT or RNXT?

Does the media favor VTVT or RNXT?

Is VTVT or RNXT more profitable?

Summary

How does RenovoRx compare to Pyxis Oncology?

Does the media prefer PYXS or RNXT?

Is PYXS or RNXT more profitable?

Which has more volatility & risk, PYXS or RNXT?

Do analysts rate PYXS or RNXT?

Do insiders and institutionals believe in PYXS or RNXT?

Which has better earnings & valuation, PYXS or RNXT?

Summary

How does RenovoRx compare to Genelux?

Which has preferable earnings & valuation, GNLX or RNXT?

Does the media prefer GNLX or RNXT?

Is GNLX or RNXT more profitable?

Do analysts rate GNLX or RNXT?

Do insiders & institutionals hold more shares of GNLX or RNXT?

Which has more volatility and risk, GNLX or RNXT?

Summary

How does RenovoRx compare to Alpha Cognition?

Do insiders and institutionals hold more shares of ACOG or RNXT?

Which has preferable earnings and valuation, ACOG or RNXT?

Do analysts prefer ACOG or RNXT?

Does the media prefer ACOG or RNXT?

Which has more volatility and risk, ACOG or RNXT?

Is ACOG or RNXT more profitable?

Summary

How does RenovoRx compare to OnKure Therapeutics?

Does the media refer more to RNXT or OKUR?

Is RNXT or OKUR more profitable?

Do insiders & institutionals have more ownership in RNXT or OKUR?

Which has preferable valuation & earnings, RNXT or OKUR?

Which has more risk and volatility, RNXT or OKUR?

Do analysts recommend RNXT or OKUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools